| INTRODUC TI ON
Alzheimer's disease (AD) is a neurological brain disease characterized by progressive memory loss and cognitive dysfunction and is the most frequent cause of dementia. At present, the etiology and pathogenesis of AD are still inconclusive. Emerging evidence has suggested that neuroinflammation, which is characterized by enhanced microglial activation probably triggered by amyloid β peptide (Aβ) deposits, plays a central role in the pathogenesis of AD. [1] [2] [3] [4] Microglia, the resident immune cells in the central nervous system (CNS), are normally activated by neuronal cell death and initiate the inflammatory response, which contributes to engulfing cell debris and decreasing Aβ deposition. 5, 6 Recently, several observations have indicated that chronic activation of NLRP3 inflammasomes in microglia is a critical and fundamental process in microglia-mediated neuroinflammation. NLRP3 inflammasome is currently the most fully characterized inflammasome, which is a molecular platforms activated upon cellular infection or stress, mainly expressed in amyloid cells and played an essential role in the Aβ-induced activation of caspase-1 and downstream secretion of its substrates, the pro-inflammatory cytokines IL-1β. 7 Inappropriate activation of NLRP3 inflammasomes contributes to the pathogenesis of AD in APP/PS1 mice. 8 Both APP/ PS1/NLRP3 −/− and APP/PS1/caspase-1 −/− mice display protection from loss of spatial memory and other AD-associated sequelae, which probably results from increased phagocytic capacity of microglia with the anti-inflammatory M2 phenotype and subsequent Aβ clearance. 9 It has been suggested that the NLRP3 inflammasome may be a promising target for inhibiting activation of microglia in AD.
Dihydromyricetin (DHM) is a plant flavonoid compound 10 that is derived from the medicinal plant Ampelopsis grossedentata and has been demonstrated to be widely used in different therapeutic areas including antioxidative, anticancer, anti-alcohol intoxication and so on. 10, 11 Substantial evidence has shown that flavonoids can cross the blood-brain barrier, 12 modulate inflammation, and exert neuroprotective effects. 13 Previous studies have shown that DHM ameliorates behavioral deficits and reverses neuropathology of AD mainly by modulating GABA A Rs, 14 which crucially involved in synaptic plasticity and made network excitability be decreased once activated in the brain, while abnormal network activity involving the loss of synapses leads to cognitive deficits in AD. 15, 16 In this study, our data demonstrate that DHM treatment provides a neuroprotective role in APP/PS1 mice by suppressing microglial activation. Furthermore, DHM treatment can reduce activated NLRP3 inflammasomes and promote Aβ clearance by increasing expression of neprilysin (NEP) or shifting microglia to the M2 phenotype in APP/PS1 mice.
| MATERIAL S AND ME THODS

| Chemicals
Dihydromyricetin (purity >98%) and dimethyl sulfoxide (DMSO)
were purchased from Sigma-Aldrich. Stock solutions of DHM were made with DMSO and diluted to final concentration in saline for injection. Injection volume was 1 mL/100 g body weight. The final DMSO concentration was 0.04%.
| Cell culture
BV-2 microglial cells were purchased from ATCC and cultured with 45 mL DMEM complete medium (contained 5 mL 10% fetal calf serum). Cells were plated into 6well microtiter plates, treated with 20 μg/mL Aβ 1-42 , which was purchased from Ana-Spec (Fremont, CA, USA). Following 24 hours incubation, the cells were activated, which was as described as previously study (16) . After 24 hours, microglia cultures were treated with an inflammatory inhibitor DHM at 2.5 μg/mL for 24 hours. 17, 18 Later cells were washed with phosphate-buffered saline (PBS) and lysed in ice-cold lysis buffer.
Lysates were centrifuged at 15 000 g for 15 minutes at 4°C. The supernatants were collected and Samples were frozen at −80°C until further analysis.
| Animals
APP/PS1 double-transgenic mice that overexpress mouse/human amyloid precursor protein (Mo/Hu APP695 SWE) and mutant human presenilin-1 (PS1-∆9) in a C57BL/6J genetic background were purchased from Beijing HFK Bio-technology Co. Ltd. (China, Beijing; certificate no. 11401300010893). The mouse genotype was confirmed by PCR using DNA extracted from tail tissues. All experimental animals were housed under standard laboratory conditions (22°C and a 12-hour light-dark cycle with free access to food and water).
Animal care and experimental protocols used in this study were conducted according to the guidelines approved by the Care and Use of Laboratory Animals of Chongqing Medical University. Efforts were made to minimize animal suffering and to reduce the number of animals used.
| Group design and drug treatment
After genotyping, 32 APP/PS1 transgenic mice at 4 months of age were randomly divided into 4 groups (n = 8): 2-week DHM-treated and control groups, 4-week DHM-treated and control groups. Mice in microglia-mediated neuroinflammation and may be a promising therapeutic drug for treating AD.
K E Y W O R D S
Alzheimer's disease, dihydromyricetin, microglia, NLRP3 inflammasome DHM treatment groups were injected with 1 mg/kg DHM intraperitoneally at the same time each day, and control mice were injected with DMSO diluted by saline. Body weight as well as food and water intake were measured every day until testing in the Morris water maze. The treatment protocol for DHM was well tolerated by the animals.
| Morris water maze
A Morris water maze was used to test spatial memory. 18 It was performed in a circular stainless-steel pool filled with opaque water. The pool was divided into 4 quadrants that were marked with a triangle, square, diamond, and circle. The temperature was set at 23 ± 1°C. A transparent escape platform (9 cm in diameter) was placed in the middle of a quadrant (goal quadrant). The procedure consisted of 1 day of visible platform tests, 2-5 consecutive days of hidden platform tests, and a spatial probe trial after the last hidden platform test. In the visible platform tests, the platform was positioned above the water surface. The mice were trained and allowed to search for the platform for 60 seconds. If a mouse did not reach the platform in the allotted time, it was placed onto it manually and allowed to stay on the platform for 10 seconds before the next trial. In the hidden platform tests, the platform was submerged 1 cm below the opaque water surface in a fixed position in the fourth quadrant. Mice were trained as before.
Escape latency and path length to reach the platform were analyzed as a measure of spatial learning and memory. In the probe trial, the platform was removed and mice were allowed to swim for 60 seconds.
The number of times that a mouse crossed the target platform location in the fourth quadrant was analyzed. Latencies and swimming paths were recorded by video tracking, and digital images were analyzed by Mater Maze software (Ethovision system, Noldus Information Technology, Wageningen, the Netherlands).
| Tissue preparation
Mice were anesthetized by 3.5% chloral hydrate and perfused with ice-cold 0.9% saline solution. The brains were dissected and divided into 2 groups; half was immediately homogenized for protein analysis, and the other half was fixed in fresh 4% paraformaldehyde After rinsing 3 times with PBS (5 min/wash), sections were incubated with species-specific secondary antibodies: CY3 or FITC488
| Immunohistochemistry
(1:200; Beyotime, Shanghai, China). To detect nuclei, DAPI (C1005;
Beyotime) was used. Sections were visualized under fluorescence microscopy, and images were analyzed using an image analysis system (ImageJ). To determine the expression of microglial cell M2
phenotypes, frozen sections were subjected to immunofluorescence. Specific methods is similar to what was mentioned before.
Sections were incubated with the following primary antibodies:
rabbit anti-arginase-1 (1:50; Biosynthesis, Beijing, China) for M2 phenotype microglia. Images were captured on a Nikon A1R + laser scanning confocal microscope (Nikon, Tokyo, Japan).
| Western blot analysis
Brain tissues were prepared in a mixture of RIPA lysis buffer (P0013B;
Beyotime) and phenylmethanesulfonyl fluoride (PMSF, ST506B;
Beyotime) on ice, followed by homogenization using a tissue homogenizer (MT-30K; China). Next, the lysates were centrifuged at 20,000 g 
| ELISA assay
| Statistical analysis
All statistical analyses were performed using Statistics 17 software.
The data are presented as mean ± standard error (SEM). To evaluate statistical significance, comparisons between 2 groups were tested using standard two-tailed unpaired t tests, and a P value <.05 was defined as significant. Morris water maze data were first analyzed by repeated measures analysis of variance (ANOVA). If P > .05, statistical comparisons were performed using one-way ANOVA, followed by Turkey's post hoc test. P < .05 was considered statistically significant. 
| RESULTS
| DHM inhibits activation of microglia in APP/
| DHM reduces NLRP3 protein expression in APP/PS1 mice
It has been reported that NLRP3 inflammasome activation is a critical cell event for chronic cerebral neuroinflammatory processes in microglia. Therefore, we evaluated whether DHM plays a role in NLRP3 inflammasomes in microglia. First, we measured These results further confirmed that DHM treatment can decrease NLRP3 inflammasome expression in APP/PS1 mice.
| DHM decreases activation of the NLRP3 inflammasome in APP/PS1 mice
Next, we examined whether DHM treatment directly inhibits activation of the NLRP3 inflammasome. Using Western blot assays, we found reduced levels of caspase-1 p20 subunits ( Figure 3C 
| DHM decreases Aβ levels and deposition
Chronic deposition of Aβ is the main trigger for NLRP3 inflammasomes during the process of AD, which probably involves chronic activation of NLRP3 inflammasomes in microglial cells. To examine whether DHM inhibits NLRP3 inflammasomes through a decrease in levels of Aβ, specific immunostaining identifying amyloid protein was performed with antibody 4G8, which recognizes the Aβ 17-24 fragment. Representative images of 4G8-positive plaques are shown in Figure 5A . Some amyloid plaques were found in the cortex and hippocampus of both 2-and 4-week DMSO-treated control mice, and more plaques of larger sizes were observed in the latter group. However, a significant decrease in the number of plaques was observed in the cortex of DHM-treated mice, and no positive plaques were seen in the hippocampus of both 2-and 4-week DHM-treated mice ( Figure 5B ,C). These data indicate that DHM can reduce Aβ deposition in the brain of APP/PS1 mice.
Next, we performed ELISA assays to measure Aβ levels in the brain. Results indicated that levels of Aβ 40 were significantly decreased after DHM administration for 2 and 4 weeks when compared with the control groups ( Figure 6A ). Similar results were obtained for Aβ 42 levels ( Figure 6B ). These data suggest that DHM can decrease Aβ levels in APP/PS1 mice.
| DHM promotes clearance of Aβ in the brains of APP/PS1 mice
To investigate the mechanism underlying the reduction in Aβ peptide levels, we examined production and clearance of Aβ. DHM had negligible effects on expression of APP full-length protein compared with DMSO-treated mice. In addition, expression of BACE1 protein, which is the major form of β-secretase, was not significantly different between DHM-and DMSO-treated groups ( Figure 6C ). These data suggest that DHM exerts little effect on production of Aβ. 
| DHM prevents cognitive deficits in APP/PS1 transgenic mice
Morris water maze tests were performed to examine whether DHM administration also affects spatial learning and memory. In the hid- 
| D ISCUSS I ON
Alzheimer's disease is a severe and prevalent disease. 19, 20 At present, available treatments for AD improve symptoms but are not successful in reversing progression of this disease. Neuroinflammation, which is characterized by activation of microglia, is known to contribute to the cascade of events culminating in the neuronal damage of AD. 21, 22 Several studies have suggested modulating neuroinflammation by targeting microglia as a treatment for AD. [23] [24] [25] However, until now, no effective drugs have been found to alleviate the microglial inflammatory reaction in AD.
It has been shown that DHM improves cognitive deficits in Swedish transgenic mice by restoring gephyrin levels and functional GABAergic transmission. 14 In our study, we also found DHM could efficiently improve memory and cognitive deficits in APP/ PS1 mice, which is an extensively used AD disease model. 26 DHM, a plant flavonoid, can cross the blood-brain barrier 12 and has antiinflammatory properties in vitro and in vivo. 27, 28 Recent research has suggested that flavonoids may be good candidates for modulating inflammation and preventing onset of neurodegenerative disorders. 13 However, it is unknown whether DHM has anti-inflammatory effects in AD. We observed a significant reduction of microglia in the hippocampus and cortex of APP/PS1 mice treated with DHM when compared with untreated APP/PS1 mice, which suggests that DHM can inhibit microglia-mediated neuroinflammation and play a neuroprotective role in AD.
Extensive evidence indicates that activation of the NLRP3 inflammasome is a critical process of the inflammatory response in disease progression of AD patients and APP/PS1 mice. 29 According to our results, the total amount of APP protein and levels of BACE1 were unaffected in DHM-treated mice, which suggests that the observed reduction of Aβ was most likely not due to reduced production of Aβ peptides and its aggregates. In contrast, levels of proteolytic enzyme NEP, which is an enzyme in microglia for Aβ clearance, 33 were increased in APP/PS1 mice treated with DHM. This suggests that DHM might promote clearance of Aβ by microglia. In addition, recent research has proposed that converting microglia from the M1 state to the M2 state increases clearance of Aβ. [34] [35] [36] [37] In our study, we showed that DHM treatment could pro- In conclusion, various studies have suggested that inhibiting activation of microglial cells may be a promising therapy for AD.
However, to date, no effective drugs have been shown to alleviate the neuroinflammatory reaction in AD. In this study, a therapeutic drug that targets inhibition of microglial activation by suppressing the NLRP3 inflammasome was demonstrated, this represents a significant contribution to AD research. However, the mechanisms through which DHM drives microglial conversion from the M1 state to the M2 state is unclear and must be the focus of further study.
| CON CLUS ION
In the present study, we demonstrates that DHM exerts neu- 
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